ES2922973T1 - Peptidos funcionalizados como agentes antivirales - Google Patents
Peptidos funcionalizados como agentes antivirales Download PDFInfo
- Publication number
- ES2922973T1 ES2922973T1 ES21846991T ES21846991T ES2922973T1 ES 2922973 T1 ES2922973 T1 ES 2922973T1 ES 21846991 T ES21846991 T ES 21846991T ES 21846991 T ES21846991 T ES 21846991T ES 2922973 T1 ES2922973 T1 ES 2922973T1
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- compound according
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003443 antiviral agent Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- 150000003839 salts Chemical class 0.000 claims abstract 15
- 238000000034 method Methods 0.000 claims abstract 10
- 241000711573 Coronaviridae Species 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract 2
- -1 substituted Chemical class 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- 108091005804 Peptidases Proteins 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000711467 Human coronavirus 229E Species 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims 1
- 241001263478 Norovirus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente invención describe compuestos de fórmula (I) y sus sales farmacéuticamente aceptables: que inhiben la actividad de replicación del coronavirus. La invención se refiere además a composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) o una de sus sales farmacéuticamente aceptables, y métodos para tratar o prevenir una infección por coronavirus en un sujeto que lo necesite, que comprenden administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de Fórmula (I) o una de sus sales farmacéuticamente aceptables. (Traducción automática con Google Translate, sin valor legal)
Claims (20)
1) hidrógeno;
2) -OH;
3) alquilo -C 1-C6 opcionalmente sustituido;
4) opcionalmente sustituido -C 3-C8 cicloalquilo;
5) heterocicloalquilo de 3 a 8 miembros opcionalmente sustituido;
6) arilo opcionalmente sustituido;
7) arilalquilo opcionalmente sustituido;
8) heteroarilo opcionalmente sustituido, y
9) heteroarilalquilo opcionalmente sustituido.
Compuesto según la reivindicación 1, en el que A se deriva de uno de los siguientes, y está opcionalmente sustituido:
Compuesto según la reivindicación 1, en el que A es -C(NRi 3Ri 4)R24R25, en el que R24 es hidrógeno, halógeno, alquilo -C 1-C6 opcionalmente sustituido, alcoxilo -C 1-C6 opcionalmente sustituido, cicloalquilo -C 3-C12 opcionalmente sustituido, heterocicloalquilo de 3 a 12 miembros opcionalmente sustituido, arilo opcionalmente sustituido, arilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo opcionalmente sustituido; R25 es hidrógeno o halógeno; y R13 y R14 son tal como se definen en la reivindicación 1.
Compuesto según la reivindicación 1, en el que X es -CN, -C(O)CH2OC(O)R2i , -C(O)CH2 C(O)2 R2 i , -C(O)CH2OR2 i , -C(O)CH2 R22 , -C(O)C(O)NHR2 i , -C(O)R2 i , -CHR2 i OC(O)R2 i , -CHR2 i C(O)2R2 i , -CHR2 i (OR2 i ) o -CH(OR2 i )2, R21 es hidrógeno, alquilo -C 1-C6 opcionalmente sustituido, cicloalquilo -C 3-C8 opcionalmente sustituido, heterocicloalquilo de 3 a 8 miembros opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; y R22 es halógeno, o -NR13R14, y R13 y R14 son tal como se definen en la reivindicación 1.
Compuesto según la reivindicación 1, representado por una de las fórmulas (IV-1) a (IV-4), o sal farmacéuticamente aceptable del mismo:
en las que R17 es halógeno, -OR16, -SR16; -NR13R14; -OC(O)NRi3Ri4; alquilo -C 1-C6 opcionalmente sustituido; cicloalquilo -C 3-C8 opcionalmente sustituido; heterocicloalquilo de 3 a 8 miembros opcionalmente sustituido;
arilo opcionalmente sustituido; o heteroarilo opcionalmente sustituido; mi es 0, 1, 2 ó 3; m2 es 0, 1,2, 3 ó 4; A, R11, R11', y X son tal como se definen en la reivindicación 1.
Compuesto según la reivindicación 1, representado por una de la fórmula (V-1), fórmula (V-2), fórmula (V-3) o fórmula (V-4), o sal farmacéuticamente aceptable del mismo:
en las que cada T es CR11; cada U es -C(RnR12)-; cada V es -O-, -S-, -C(RnR12)-, o
-N(R13 R14)-; m es 0, 1 ó 2; m' es 0, 1, 2 ó 3; y A, Q, n2, R11, R12, R13, R14, y X son tal como se definen en la reivindicación 1.
Compuesto según la reivindicación 1, representado por una de las fórmulas (VI-1a) a (VI-8a), o sal farmacéuticamente aceptable del mismo:
en las que X y A son tal como se definen en la reivindicación 1.
Compuesto según la reivindicación 1, representado por una de las fórmulas (IX-1) a (IX-8), o sal farmacéuticamente aceptable del mismo:
en las que R32 es hidrógeno, -F, Cl, -CH3, -CF3 o -OR; R33 es -Cl, -Br, -OR21, -NHR21, o -OC(O)R2i ; R34 es R21; R21 es hidrógeno, alquilo -C 1-C6 opcionalmente sustituido, cicloalquilo -C 3-C8 opcionalmente sustituido, heterocicloalquilo de 3 a 8 miembros opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; y A son tal como se definen en la reivindicación 1.
9. Compuesto según la reivindicación 1, representado por una de las fórmulas (IX-1) a (IX-8), o sal farmacéuticamente aceptable del mismo:
en las que R24 es hidrógeno, halógeno, alquilo -C 1-C6 opcionalmente sustituido, alcoxilo -C 1-C6 opcionalmente sustituido, cicloalquilo -C 3-C12 opcionalmente sustituido, heterocicloalquilo de 3 a 12 miembros opcionalmente sustituido, arilo opcionalmente sustituido, arilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo opcionalmente sustituido; R25 es hidrógeno o halógeno; y X, R13 y R14 son tal como se definen en la reivindicación 1.
10. Compuesto según la reivindicación 1, representado por una de las fórmulas (XIII-1) a (XIII-4), o sal farmacéuticamente aceptable del mismo:
en las que R24 es hidrógeno, halógeno, alquilo -C 1-C6 opcionalmente sustituido, alcoxilo -C 1-C6 opcionalmente sustituido, cicloalquilo -C 3-C12 opcionalmente sustituido, heterocicloalquilo de 3 a 12 miembros opcionalmente sustituido, arilo opcionalmente sustituido, arilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo opcionalmente sustituido; y R15 y X son tal como se definen en la reivindicación 1.
12. Composición farmacéutica que comprende un compuesto según una cualquiera de las reivindicaciones 1 a 11 y un portador o excipiente farmacéuticamente aceptable.
13. Método de tratamiento o prevención de una infección por virus, incluyendo una infección por virus de un virus a base de ARN, un coronavirus, un rinovirus y un norovirus, en un sujeto susceptible de o que padece infección por virus, comprendiendo el método administrar al sujeto un inhibidor de una enzima 3C proteasa en el que el inhibidor es un compuesto según una cualquiera de las reivindicaciones 1 a 11, o una sal farmacéuticamente aceptable.
14. Método de tratamiento o prevención de una infección por coronavirus en un sujeto que lo necesita, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto o una combinación de compuestos según una cualquiera de las reivindicaciones 1 a 11, o una sal farmacéuticamente aceptable.
15. Método según la reivindicación 13, en el que el virus es un coronavirus seleccionado de un coronavirus 229E, NL63, OC43, HKU1, SARS-CoV o MERS.
16. Método de tratamiento o prevención de una infección por virus en un sujeto susceptible a o que padece la infección por virus que comprende administrar al sujeto un inhibidor de una enzima 3C proteasa en el que el inhibidor comprende un compuesto según una cualquiera de las reivindicaciones 1 a 11, o una sal farmacéuticamente aceptable del mismo.
17. Método de inhibición de 3C proteasa viral o 3CL proteasa viral en un mamífero, que comprende administrar a dicho sujeto una cantidad eficaz de un compuesto según una cualquiera de las reivindicaciones 1 a 11, o una sal farmacéuticamente aceptable del mismo.
18. Método según la reivindicación 17, en el que el sujeto es un humano.
19. Método de tratamiento de un trastorno respiratorio, que incluye asma aguda, enfermedad pulmonar secundaria a exposiciones ambientales, infección pulmonar aguda, infección pulmonar crónica, en un sujeto que lo necesita, que comprende administrar al sujeto un compuesto según una cualquiera de las reivindicaciones 1 a 11.
20. Método según la reivindicación 19, en el que el compuesto o la composición farmacéutica se administra por vía oral, por vía subcutánea, por vía intravenosa o por inhalación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063054048P | 2020-07-20 | 2020-07-20 | |
PCT/US2021/042193 WO2022020242A1 (en) | 2020-07-20 | 2021-07-19 | Functionalized peptides as antiviral agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2922973T1 true ES2922973T1 (es) | 2022-09-22 |
Family
ID=79729492
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES202290062A Pending ES2936277R1 (es) | 2020-07-20 | 2021-07-19 | Peptidos funcionalizados como agentes antivirales |
ES21846991T Pending ES2922973T1 (es) | 2020-07-20 | 2021-07-19 | Peptidos funcionalizados como agentes antivirales |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES202290062A Pending ES2936277R1 (es) | 2020-07-20 | 2021-07-19 | Peptidos funcionalizados como agentes antivirales |
Country Status (17)
Country | Link |
---|---|
US (3) | US20220033383A1 (es) |
EP (1) | EP4051265A4 (es) |
JP (1) | JP2023535701A (es) |
KR (1) | KR20230069090A (es) |
CN (1) | CN116348477A (es) |
AU (1) | AU2021313130A1 (es) |
BR (1) | BR112022026899A2 (es) |
CA (1) | CA3173964A1 (es) |
CL (1) | CL2023000167A1 (es) |
CO (1) | CO2023000199A2 (es) |
DE (3) | DE112021000413B4 (es) |
ES (2) | ES2936277R1 (es) |
GB (2) | GB2607514B (es) |
HU (1) | HUE21846991T1 (es) |
IL (1) | IL300027A (es) |
MX (1) | MX2023000798A (es) |
WO (1) | WO2022020242A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11124497B1 (en) * | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CA3201360A1 (en) | 2021-04-16 | 2022-10-20 | Shuhui Chen | Ring-modified proline short peptide compound and use thereof |
WO2022266363A1 (en) * | 2021-06-16 | 2022-12-22 | The Scripps Research Institute | Protease inhibitors for the treatment of coronavirus infections |
US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023088418A1 (en) * | 2021-11-20 | 2023-05-25 | Fochon Biosciences, Ltd. | Compounds as sars-cov-2 inhibitors |
WO2023116811A1 (zh) * | 2021-12-22 | 2023-06-29 | 福建广生中霖生物科技有限公司 | 含β-胺基酮的短肽化合物及其应用 |
TW202334123A (zh) * | 2021-12-31 | 2023-09-01 | 大陸商蘇州愛科百發生物醫藥技術有限公司 | 用於預防和治療冠狀病毒感染的化合物及其偶聯物和方法 |
WO2023134730A1 (zh) * | 2022-01-13 | 2023-07-20 | 先声再明医药有限公司 | 一种酰胺类抗病毒化合物 |
US11760722B2 (en) | 2022-01-18 | 2023-09-19 | Ascletis Bioscience Co., Ltd. | Inhibitors of cysteine proteases and methods of use thereof |
CN114230504B (zh) * | 2022-02-24 | 2022-06-03 | 南京桦冠生物技术有限公司 | 一种吡咯烷酮中间体的合成方法 |
CN116768967A (zh) * | 2022-03-07 | 2023-09-19 | 广州谷森制药有限公司 | 氘代内酰胺类化合物及其制备方法、组合物和用途 |
CN114957383A (zh) * | 2022-04-01 | 2022-08-30 | 中国科学院上海药物研究所 | 一种拟肽类化合物及其制备方法、药物组合物和用途 |
WO2024059087A1 (en) * | 2022-09-13 | 2024-03-21 | Takeda Pharmaceutical Company Limited | 3-(1h-indole-2-carbonyl)-6,6-dimethyl-n-((s)-1-oxo-3-((s)-2-oxopyrrolidin-3-yl)p ropan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide derivatives as mpro inhibitors for the treatment of coronavirus infections |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
EP1628674A2 (en) | 2003-05-06 | 2006-03-01 | Cytovia, Inc. | Protease inhibitors for coronaviruses and sars-cov and the use thereof |
DE602004011047T2 (de) | 2003-05-13 | 2008-12-24 | Universität Zu Lübeck | Kristallstruktur von der humanen coronavirus 229e hauptproteinase und deren verwendung zur entwicklung von sars-inhibitoren |
US20060014821A1 (en) * | 2003-08-27 | 2006-01-19 | Agouron Pharmaceuticals, Inc. | Inhibitors of SARS 3C like protease |
US7462594B2 (en) | 2003-12-31 | 2008-12-09 | Taigen Biotechnology Co., Ltd. | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases |
WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
WO2006061714A2 (en) | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
EP1783228A1 (en) | 2005-11-08 | 2007-05-09 | ETH Zürich | Recombinant expression of multiprotein complexes using polygenes |
CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
JP4546578B2 (ja) | 2006-07-05 | 2010-09-15 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ |
CN102459575A (zh) | 2009-06-05 | 2012-05-16 | 细胞动力国际有限公司 | 重编程t细胞和造血细胞的方法 |
US9008723B2 (en) * | 2010-01-08 | 2015-04-14 | United States Foundation For Inspiration And Recognition Of Science And Technology | Wireless adapter |
ES2670842T3 (es) | 2010-06-15 | 2018-06-01 | Cellular Dynamics International, Inc. | Generación de células madre pluripotentes inducidas a partir de pequeños volúmenes de sangre periférica |
EP2760827A4 (en) | 2011-09-27 | 2015-06-24 | Univ Kansas State | ANTIVIRAL MEDIUM WITH A WIDE SPECTRUM AGAINST 3C OR 3C-SIMILAR PROTEASES FROM PICORNIVIRUS SUPERCLUSTS: PICORNIVERS, CALICIVIRES AND CORONA VIRUSES |
US9688978B2 (en) | 2011-12-29 | 2017-06-27 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetase-Fc conjugates |
US9828342B2 (en) | 2012-02-24 | 2017-11-28 | City Of Hope | Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof |
EP2844249A4 (en) | 2012-05-02 | 2016-03-09 | Univ Kansas State | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS VIRUZIDES AGAINST 3C OR 3C LIKE PROTEASES OF PICORNIVERS, CALICIVIRES AND CORONA VIRUSES |
US9791436B2 (en) | 2012-09-12 | 2017-10-17 | The University Of Queensland | Protease-based biosensor |
RU2018138576A (ru) | 2013-01-11 | 2019-04-02 | Импоссибл Фудз Инк. | Немолочный аналог сыра, содержащий коацерват |
US9255254B2 (en) | 2013-02-08 | 2016-02-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Nylanderia fulva virus |
US9587235B2 (en) | 2013-03-15 | 2017-03-07 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
EP3044322A4 (en) | 2013-09-12 | 2017-09-06 | The University Of Queensland | Bimolecular protease-based biosensor |
GB201320351D0 (en) | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
IL296691B2 (en) | 2014-04-25 | 2023-11-01 | 2Seventy Bio Inc | MND promoter chimeric antigen receptors |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
SG11201610170SA (en) | 2014-06-06 | 2017-01-27 | Bluebird Bio Inc | Improved t cell compositions |
WO2016014522A1 (en) | 2014-07-21 | 2016-01-28 | Brandeis University | Inhibitors of deubiquitinating proteases |
GB201413020D0 (en) | 2014-07-23 | 2014-09-03 | Pribright The Inst | Coronavirus |
US9328147B2 (en) | 2014-09-05 | 2016-05-03 | Chung Yuan Christian University | Recombinant baculovirus vector and uses thereof |
KR102584938B1 (ko) | 2014-12-12 | 2023-10-05 | 2세븐티 바이오, 인코포레이티드 | Bcma 키메릭 항원 수용체 |
CN113769079A (zh) | 2015-02-27 | 2021-12-10 | 衣阿华州立大学研究基金会股份有限公司 | 猪流行性腹泻病毒株和由其产生的免疫原性组合物 |
US10784994B2 (en) | 2015-08-21 | 2020-09-22 | Lg Electronics Inc. | Method for transmitting information for LTE-WLAN aggregation system and a device therefor |
WO2017044507A2 (en) | 2015-09-08 | 2017-03-16 | Sirnaomics, Inc. | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection |
US10590084B2 (en) | 2016-03-09 | 2020-03-17 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
US9975885B2 (en) | 2016-04-28 | 2018-05-22 | Purdue Research Foundation | Broad-spectrum non-covalent coronavirus protease inhibitors |
CA3024120A1 (en) | 2016-05-13 | 2017-11-16 | Emory University | Peptidomimetics for the treatment of norovirus infection |
WO2017222935A1 (en) | 2016-06-20 | 2017-12-28 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
WO2018023054A1 (en) | 2016-07-28 | 2018-02-01 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
UY37381A (es) * | 2016-08-30 | 2018-03-23 | Glaxosmithkline Ip No 2 Ltd | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos |
SG10201912574WA (en) | 2016-09-28 | 2020-02-27 | Blade Therapeutics Inc | Calpain modulators and therapeutic uses thereof |
CA3064014A1 (en) | 2017-05-25 | 2018-11-29 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
MX2021014742A (es) | 2019-06-05 | 2022-02-11 | Univ Emory | Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus. |
US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
US20230105838A1 (en) | 2020-04-05 | 2023-04-06 | Pfizer Inc. | Method of Treating COVID-19 |
US20230148179A1 (en) | 2020-04-08 | 2023-05-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF |
CA3179697A1 (en) | 2020-04-10 | 2021-10-14 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
WO2021206877A1 (en) | 2020-04-10 | 2021-10-14 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
WO2021226546A1 (en) * | 2020-05-08 | 2021-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Protease inhibitors for treatment or prevention of coronavirus disease |
US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
KR20230040386A (ko) * | 2020-06-09 | 2023-03-22 | 파르데스 바이오사이언시스, 인크. | 시스테인 프로테아제의 억제제 및 이의 사용 방법 |
AU2021289665A1 (en) | 2020-06-10 | 2022-12-15 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
WO2022013684A1 (en) * | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
US10959969B1 (en) | 2020-07-24 | 2021-03-30 | Lanny L Johnson | Methods of treating SARS Cov-2 virus with protocatechuic acid |
WO2022020711A1 (en) | 2020-07-24 | 2022-01-27 | The Texas A&M University System | Sars-cov-2 main protease inhibitors |
CN115960088A (zh) * | 2020-07-31 | 2023-04-14 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
US11351149B2 (en) * | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CA3201360A1 (en) * | 2021-04-16 | 2022-10-20 | Shuhui Chen | Ring-modified proline short peptide compound and use thereof |
WO2022251615A1 (en) * | 2021-05-28 | 2022-12-01 | Arun K Ghosh | Compounds for the treatment of sars |
CA3220847A1 (en) * | 2021-06-02 | 2022-12-08 | Long Mao | Protease inhibitors as antivirals |
JPWO2023286844A1 (es) * | 2021-07-15 | 2023-01-19 |
-
2021
- 2021-07-19 GB GB2211934.1A patent/GB2607514B/en active Active
- 2021-07-19 JP JP2023504063A patent/JP2023535701A/ja active Pending
- 2021-07-19 US US17/379,409 patent/US20220033383A1/en not_active Abandoned
- 2021-07-19 MX MX2023000798A patent/MX2023000798A/es unknown
- 2021-07-19 DE DE112021000413.1T patent/DE112021000413B4/de active Active
- 2021-07-19 DE DE21846991.4T patent/DE21846991T1/de active Pending
- 2021-07-19 IL IL300027A patent/IL300027A/en unknown
- 2021-07-19 ES ES202290062A patent/ES2936277R1/es active Pending
- 2021-07-19 DE DE202021004113.3U patent/DE202021004113U1/de active Active
- 2021-07-19 AU AU2021313130A patent/AU2021313130A1/en active Pending
- 2021-07-19 ES ES21846991T patent/ES2922973T1/es active Pending
- 2021-07-19 WO PCT/US2021/042193 patent/WO2022020242A1/en unknown
- 2021-07-19 EP EP21846991.4A patent/EP4051265A4/en active Pending
- 2021-07-19 GB GB2306834.9A patent/GB2619610A/en active Pending
- 2021-07-19 HU HUE21846991A patent/HUE21846991T1/hu unknown
- 2021-07-19 CA CA3173964A patent/CA3173964A1/en active Pending
- 2021-07-19 BR BR112022026899A patent/BR112022026899A2/pt not_active Application Discontinuation
- 2021-07-19 KR KR1020237005438A patent/KR20230069090A/ko unknown
- 2021-07-19 CN CN202180059223.3A patent/CN116348477A/zh active Pending
- 2021-10-21 US US17/506,981 patent/US20220041652A1/en not_active Abandoned
- 2021-11-09 US US17/522,176 patent/US11358953B2/en active Active
-
2023
- 2023-01-11 CO CONC2023/0000199A patent/CO2023000199A2/es unknown
- 2023-01-18 CL CL2023000167A patent/CL2023000167A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022026899A2 (pt) | 2023-01-24 |
GB2619610A (en) | 2023-12-13 |
JP2023535701A (ja) | 2023-08-21 |
ES2936277A2 (es) | 2023-03-15 |
US20220033383A1 (en) | 2022-02-03 |
US20220041652A1 (en) | 2022-02-10 |
IL300027A (en) | 2023-03-01 |
CN116348477A (zh) | 2023-06-27 |
GB2607514A (en) | 2022-12-07 |
GB202306834D0 (en) | 2023-06-21 |
GB2607514B (en) | 2023-06-21 |
HUE21846991T1 (hu) | 2022-09-28 |
WO2022020242A1 (en) | 2022-01-27 |
KR20230069090A (ko) | 2023-05-18 |
MX2023000798A (es) | 2023-02-27 |
DE112021000413B4 (de) | 2023-02-23 |
DE112021000413T5 (de) | 2022-12-01 |
CL2023000167A1 (es) | 2023-09-08 |
AU2021313130A1 (en) | 2023-02-09 |
US11358953B2 (en) | 2022-06-14 |
DE21846991T1 (de) | 2022-07-21 |
US20220073499A1 (en) | 2022-03-10 |
CO2023000199A2 (es) | 2023-04-17 |
DE202021004113U1 (de) | 2022-08-29 |
ES2936277R1 (es) | 2023-04-18 |
GB202211934D0 (en) | 2022-09-28 |
CA3173964A1 (en) | 2022-01-27 |
EP4051265A1 (en) | 2022-09-07 |
EP4051265A4 (en) | 2022-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2922973T1 (es) | Peptidos funcionalizados como agentes antivirales | |
CN107312039B (zh) | 一种替诺福韦前药的制备方法 | |
JP2013544812A5 (es) | ||
RU2009102252A (ru) | Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с | |
JP2014503516A5 (es) | ||
AR062270A1 (es) | Compuestos de heteroarilo inhibidores de enzimas de activacion e1, composiciones farmaceuticas que los contienen y usos en desordenes asociados a proliferacion celular,tales como canceres y trastornos inflamatorios. | |
JP2007502845A (ja) | がんまたはウイルス疾患を治療するための三環性複素環化合物、組成物および方法 | |
CN106167504A (zh) | 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用 | |
CA2656716C (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique | |
RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
JP5998139B2 (ja) | 1,5−ジフェニル−ペンタ−1,4−ジエン−3−オン化合物 | |
CN112110877B (zh) | 苯并异硒唑酮衍生物、制备方法及在抗冠状病毒药物中应用 | |
JP2008521908A5 (es) | ||
RU2004122918A (ru) | Производные индолина, используемые как ингибиторы протеинкиназы | |
JP2009501234A5 (es) | ||
JP2022137237A5 (es) | ||
RU2007125658A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
CA3200437A1 (en) | Compounds for the treatment of sars | |
RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
EP2139463B1 (en) | Anti-infective agents | |
CN110662752B (zh) | 用于临床管理由衰老细胞引起或介导的病症以及治疗癌症的Bcl家族拮抗剂磷杂环化合物 | |
JP2005526773A5 (es) | ||
Ding et al. | Synthesis of thiazolone-based sulfonamides as inhibitors of HCV NS5B polymerase | |
KR860008973A (ko) | 2-피롤리돈 유도체 | |
WO2012051912A1 (zh) | 含氮类联苯化合物,含其的药物组合物,其制备方法及其在抗hiv-1中的应用 |